BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Turky A, Bayoumi AH, Ghiaty A, El-Azab AS, A-M Abdel-Aziz A, Abulkhair HS. Design, synthesis, and antitumor activity of novel compounds based on 1,2,4-triazolophthalazine scaffold: Apoptosis-inductive and PCAF-inhibitory effects. Bioorg Chem 2020;101:104019. [PMID: 32615465 DOI: 10.1016/j.bioorg.2020.104019] [Cited by in Crossref: 15] [Cited by in F6Publishing: 19] [Article Influence: 7.5] [Reference Citation Analysis]
Number Citing Articles
1 Othman EM, Fayed EA, Husseiny EM, Abulkhair HS. Apoptosis induction, PARP-1 inhibition, and cell cycle analysis of leukemia cancer cells treated with novel synthetic 1,2,3-triazole-chalcone conjugates. Bioorganic Chemistry 2022;123:105762. [DOI: 10.1016/j.bioorg.2022.105762] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
2 Bass AKA, Nageeb EM, El-Zoghbi MS, Mohamed MFA, Badr M, Abuo-Rahma GEA. Utilization of cyanopyridine in design and synthesis of first-in-class anticancer dual acting PIM-1 kinase/HDAC inhibitors. Bioorg Chem 2021;119:105564. [PMID: 34959179 DOI: 10.1016/j.bioorg.2021.105564] [Reference Citation Analysis]
3 Fareed MR, Shoman ME, Hamed MIA, Badr M, Bogari HA, Elhady SS, Ibrahim TS, Abuo-Rahma GEA, Ali TFS. New Multi-Targeted Antiproliferative Agents: Design and Synthesis of IC261-Based Oxindoles as Potential Tubulin, CK1 and EGFR Inhibitors. Pharmaceuticals (Basel) 2021;14:1114. [PMID: 34832895 DOI: 10.3390/ph14111114] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
4 El-Adl K, Ibrahim MK, Khedr F, Abulkhair HS, Eissa IH. Design, synthesis, docking, and anticancer evaluations of phthalazines as VEGFR-2 inhibitors. Arch Pharm (Weinheim) 2021;:e2100278. [PMID: 34596910 DOI: 10.1002/ardp.202100278] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
5 Gaber AA, El-Morsy AM, Sherbiny FF, Bayoumi AH, El-Gamal KM, El-Adl K, Al-Karmalawy AA, Ezz Eldin RR, Saleh MA, Abulkhair HS. Pharmacophore-linked pyrazolo[3,4-d]pyrimidines as EGFR-TK inhibitors: Synthesis, anticancer evaluation, pharmacokinetics, and in silico mechanistic studies. Arch Pharm (Weinheim) 2021;:e2100258. [PMID: 34467546 DOI: 10.1002/ardp.202100258] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 11.0] [Reference Citation Analysis]
6 Khedr F, Ibrahim MK, Eissa IH, Abulkhair HS, El-Adl K. Phthalazine-based VEGFR-2 inhibitors: Rationale, design, synthesis, in silico, ADMET profile, docking, and anticancer evaluations. Arch Pharm (Weinheim) 2021;354:e2100201. [PMID: 34411344 DOI: 10.1002/ardp.202100201] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
7 Khalil NA, Ahmed EM, Zaher AF, Sobh EA, El-Sebaey SA, El-Zoghbi MS. New benzothieno[2,3-c]pyridines as non-steroidal CYP17 inhibitors: design, synthesis, anticancer screening, apoptosis induction, and in silico ADME profile studies. J Enzyme Inhib Med Chem 2021;36:1839-59. [PMID: 34338119 DOI: 10.1080/14756366.2021.1958212] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Fares S, Selim KB, Goda FE, El-Sayed MAA, AlSaif NA, Hefnawy MM, Abdel-Aziz AA, El-Azab AS. Design, synthesis, and analysis of antiproliferative and apoptosis-inducing activities of nitrile derivatives containing a benzofuran scaffold: EGFR inhibition assay and molecular modelling study. J Enzyme Inhib Med Chem 2021;36:1488-99. [PMID: 34227457 DOI: 10.1080/14756366.2021.1946044] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 El-Shershaby MH, Ghiaty A, Bayoumi AH, Al-Karmalawy AA, Husseiny EM, El-Zoghbi MS, Abulkhair HS. From triazolophthalazines to triazoloquinazolines: A bioisosterism-guided approach toward the identification of novel PCAF inhibitors with potential anticancer activity. Bioorg Med Chem 2021;42:116266. [PMID: 34126285 DOI: 10.1016/j.bmc.2021.116266] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 30.0] [Reference Citation Analysis]
10 El-Adl K, Sakr H, El-Hddad SSA, El-Helby AA, Nasser M, Abulkhair HS. Design, synthesis, docking, ADMET profile, and anticancer evaluations of novel thiazolidine-2,4-dione derivatives as VEGFR-2 inhibitors. Arch Pharm (Weinheim) 2021;354:e2000491. [PMID: 33788290 DOI: 10.1002/ardp.202000491] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
11 Rizk SA, El-Hashash MA, Youssef AA, Elgendy AT. A green microwave method for synthesizing a more stable phthalazin-1-ol isomer as a good anticancer reagent using chemical plasma organic reactions. Heliyon 2021;7:e06220. [PMID: 33748447 DOI: 10.1016/j.heliyon.2021.e06220] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
12 Abulkhair HS, Elmeligie S, Ghiaty A, El-Morsy A, Bayoumi AH, Ahmed HEA, El-Adl K, Zayed MF, Hassan MH, Akl EN, El-Zoghbi MS. In vivo- and in silico-driven identification of novel synthetic quinoxalines as anticonvulsants and AMPA inhibitors. Arch Pharm (Weinheim) 2021;354:e2000449. [PMID: 33559320 DOI: 10.1002/ardp.202000449] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
13 El-shershaby MH, Ghiaty A, Bayoumi AH, Ahmed HEA, El-zoghbi MS, El-adl K, Abulkhair HS. 1,2,4-Triazolo[4,3- c ]quinazolines: a bioisosterism-guided approach towards the development of novel PCAF inhibitors with potential anticancer activity. New J Chem 2021;45:11136-52. [DOI: 10.1039/d1nj00710f] [Cited by in Crossref: 4] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
14 El-shershaby MH, El-gamal KM, Bayoumi AH, El-adl K, Alswah M, Ahmed HEA, Al-karmalamy AA, Abulkhair HS. The antimicrobial potential and pharmacokinetic profiles of novel quinoline-based scaffolds: synthesis and in silico mechanistic studies as dual DNA gyrase and DHFR inhibitors. New J Chem 2021;45:13986-4004. [DOI: 10.1039/d1nj02838c] [Cited by in Crossref: 13] [Cited by in F6Publishing: 19] [Article Influence: 13.0] [Reference Citation Analysis]
15 El-Adl K, Ibrahim MK, Khedr F, Abulkhair HS, Eissa IH. N-Substituted-4-phenylphthalazin-1-amine-derived VEGFR-2 inhibitors: Design, synthesis, molecular docking, and anticancer evaluation studies. Arch Pharm (Weinheim) 2021;354:e2000219. [PMID: 33197080 DOI: 10.1002/ardp.202000219] [Cited by in Crossref: 4] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
16 Zaib S, Khan I. Synthetic and medicinal chemistry of phthalazines: Recent developments, opportunities and challenges. Bioorg Chem 2020;105:104425. [PMID: 33157344 DOI: 10.1016/j.bioorg.2020.104425] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
17 El-Shershaby MH, El-Gamal KM, Bayoumi AH, El-Adl K, Ahmed HEA, Abulkhair HS. Synthesis, antimicrobial evaluation, DNA gyrase inhibition, and in silico pharmacokinetic studies of novel quinoline derivatives. Arch Pharm (Weinheim) 2021;354:e2000277. [PMID: 33078877 DOI: 10.1002/ardp.202000277] [Cited by in Crossref: 7] [Cited by in F6Publishing: 16] [Article Influence: 3.5] [Reference Citation Analysis]
18 Turky A, Sherbiny FF, Bayoumi AH, Ahmed HEA, Abulkhair HS. Novel 1,2,4-triazole derivatives: Design, synthesis, anticancer evaluation, molecular docking, and pharmacokinetic profiling studies. Arch Pharm (Weinheim) 2020;353:e2000170. [PMID: 32893368 DOI: 10.1002/ardp.202000170] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
19 Turky A, Bayoumi AH, Sherbiny FF, El-Adl K, Abulkhair HS. Unravelling the anticancer potency of 1,2,4-triazole-N-arylamide hybrids through inhibition of STAT3: synthesis and in silico mechanistic studies. Mol Divers 2021;25:403-20. [PMID: 32830299 DOI: 10.1007/s11030-020-10131-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 21] [Article Influence: 2.5] [Reference Citation Analysis]